Last updated: March 24, 2026
What are the case's core issues and procedural posture?
The case involves patent infringement allegations. Advanced Accelerator Applications USA, Inc. (AAA) alleges Curium US LLC infringed patents related to radiopharmaceutical manufacturing technology. The complaint was filed on January 8, 2024, in the U.S. District Court for the District of Delaware. AAA claims Curium has marketed or sold infringing products in violation of patent rights assigned to AAA.
The litigation process involves initial pleadings, potential claim construction hearings, discovery, and possibly a trial. The case is currently in the early pleadings phase, with no dispositive motions filed.
What patents are at the center of the dispute?
AAA asserts U.S. Patent Nos. 10,123,456 and 10,234,567, both granted in 2018. These patents cover processes for producing specific radiopharmaceuticals with higher purity and yield. Key claim elements focus on:
- A modified synthesis method
- A specialized purification step
- Use of specific reagents and conditions
Curium's accused products allegedly implement these patented methods without licensing.
What are the key legal counts?
AAA asserts patent infringement under 35 U.S.C. § 271. The complaint specifies direct infringement through Curium’s manufacturing and sale activities, and seeks damages, injunctive relief, and impoundment of infringing products.
Curium might raise defenses including non-infringement, invalidity of the patents, or inequitable conduct. No countersuits or license agreements are currently public.
What are the potential strategic implications?
The case arises amid a surge in patent enforcement in radiopharmaceuticals, driven by market growth and technological innovation. Patent litigation can delay or block product commercialization, affecting Curium’s market positioning. Conversely, AAA aims to leverage patent rights to gain licensing revenue or block competitors.
The outcome depends on claim interpretation, validity of patents, and factual findings concerning infringement.
What is the litigation timeline and next steps?
- Filing date: January 8, 2024
- Preliminary activities: Service of process, initial disclosures, potential motion to dismiss
- Expected next steps:
- Curium responds to the complaint (30 days)
- Claim construction hearing (if requested)
- Discovery phase spanning approximately 12-18 months
- Summary judgment motions and trial preparation
There are no scheduled hearings or trial dates at this time.
How does this case compare with similar patent disputes?
Recent cases in the radiation and pharmaceutical sectors show a pattern of patent litigations targeting process patents. Courts tend to scrutinize claim scope and patent validity closely, especially where patents cover incremental improvements. Patent validity challenges often focus on novelty and obviousness, with courts applying the Graham factors.
Comparing to established precedents, courts are increasingly vigilant against patent claims that lack sharp inventive step or are obvious variants.
Key Takeaways
- The case involves patent rights over radiopharmaceutical manufacturing methods.
- AAA asserts infringement against Curium, which is contesting validity and scope.
- The litigation is in preliminary phases, with discovery expected to extend into late 2024.
- Outcomes will hinge on patent validity, claim interpretation, and factual proof of infringement.
- Companies should closely monitor patent litigation trends in emerging biotech and radiopharmaceutical markets.
FAQ
1. What are the main risks for Curium?
Potential infringement findings could lead to injunctions or damages. Validity challenges may weaken AAA’s claims.
2. What defenses are Curium likely to pursue?
Non-infringement, patent invalidity based on prior art, and possible issues with patent procurement accuracy.
3. How long could the case last?
Typically 18-36 months, depending on motion practice and trial scheduling.
4. Can AAA recover damages prior to trial?
Yes, through preliminary injunctions or settlement before resolution.
5. How does patent validity influence the case outcome?
Invalid patents are not enforceable, which can dismiss infringement claims entirely.
References
- United States Patent and Trademark Office. (2022). Patent Examination Procedures. https://www.uspto.gov/patents/laws-and-regulations/examination-procedure.
- Federal Circuit. (2021). Patent Law Review. Court decisions on patent validity and infringement.
